XNCR – Xencor Inc
XNCR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
16.28
Margin Of Safety %
Put/Call OI Ratio
1.53
EPS Next Q Diff
-0.67
EPS Last/This Y
-1.84
EPS This/Next Y
0.09
Price
12.3
Target Price
28.42
Analyst Recom
1.36
Performance Q
-13.74
Upside
-321.6%
Beta
1.01
Ticker: XNCR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | XNCR | 11.86 | 2.88 | 999.99 | 361 |
| 2026-03-10 | XNCR | 11.98 | 2.99 | 999.99 | 371 |
| 2026-03-11 | XNCR | 12.04 | 3.10 | 0.00 | 381 |
| 2026-03-12 | XNCR | 11.62 | 3.10 | 0.00 | 381 |
| 2026-03-13 | XNCR | 11.61 | 3.10 | 0.00 | 381 |
| 2026-03-17 | XNCR | 11.75 | 3.20 | 999.99 | 391 |
| 2026-03-18 | XNCR | 11.6 | 3.20 | 999.99 | 391 |
| 2026-03-20 | XNCR | 12.12 | 3.20 | 999.99 | 391 |
| 2026-03-25 | XNCR | 12.41 | 1.32 | 999.99 | 332 |
| 2026-03-26 | XNCR | 12.32 | 1.41 | 999.99 | 345 |
| 2026-03-27 | XNCR | 11.44 | 1.52 | 999.99 | 361 |
| 2026-03-30 | XNCR | 11.36 | 1.52 | 999.99 | 361 |
| 2026-03-31 | XNCR | 12.06 | 1.64 | 0.00 | 377 |
| 2026-04-01 | XNCR | 12.52 | 1.64 | 0.00 | 377 |
| 2026-04-06 | XNCR | 12.44 | 1.53 | 1.00 | 387 |
| 2026-04-07 | XNCR | 12.3 | 1.53 | 1.00 | 387 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | XNCR | 11.86 | -13.1 | - | -2.98 |
| 2026-03-10 | XNCR | 11.98 | -13.1 | - | -2.98 |
| 2026-03-11 | XNCR | 12.03 | -13.1 | - | -2.98 |
| 2026-03-12 | XNCR | 11.61 | -13.1 | - | -2.98 |
| 2026-03-13 | XNCR | 12.03 | -13.1 | - | -2.98 |
| 2026-03-17 | XNCR | 11.75 | -13.1 | - | -2.98 |
| 2026-03-18 | XNCR | 11.60 | -13.1 | - | -2.98 |
| 2026-03-19 | XNCR | 12.10 | -13.1 | - | -2.98 |
| 2026-03-20 | XNCR | 12.13 | -13.1 | - | -2.98 |
| 2026-03-23 | XNCR | 12.05 | -13.1 | - | -2.98 |
| 2026-03-24 | XNCR | 11.91 | -13.1 | - | -2.98 |
| 2026-03-25 | XNCR | 12.40 | -13.1 | - | -2.98 |
| 2026-03-26 | XNCR | 12.31 | -13.1 | - | -2.98 |
| 2026-03-27 | XNCR | 11.45 | -13.1 | - | -2.98 |
| 2026-03-30 | XNCR | 11.37 | -13.1 | - | -3.08 |
| 2026-03-31 | XNCR | 12.05 | -13.1 | - | -3.08 |
| 2026-04-01 | XNCR | 12.52 | -13.1 | - | -3.08 |
| 2026-04-02 | XNCR | 12.82 | -13.1 | - | -3.08 |
| 2026-04-06 | XNCR | 12.44 | -13.1 | - | -3.08 |
| 2026-04-07 | XNCR | 12.30 | -13.1 | - | -3.08 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | XNCR | -4.98 | -6.46 | 15.96 |
| 2026-03-10 | XNCR | -4.98 | -6.46 | 15.96 |
| 2026-03-11 | XNCR | -4.98 | -6.46 | 16.32 |
| 2026-03-12 | XNCR | -4.98 | -6.46 | 16.32 |
| 2026-03-13 | XNCR | -4.98 | -6.46 | 16.32 |
| 2026-03-18 | XNCR | -4.98 | -6.49 | 16.32 |
| 2026-03-19 | XNCR | -4.98 | -6.49 | 16.32 |
| 2026-03-20 | XNCR | -4.98 | -6.49 | 16.32 |
| 2026-03-23 | XNCR | -4.98 | -6.47 | 16.32 |
| 2026-03-24 | XNCR | -4.98 | -6.47 | 16.32 |
| 2026-03-25 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-03-26 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-03-27 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-03-30 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-03-31 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-04-01 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-04-02 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-04-06 | XNCR | -4.98 | -6.47 | 16.28 |
| 2026-04-07 | XNCR | -4.98 | -6.47 | 16.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.09
Avg. EPS Est. Current Quarter
-0.75
Avg. EPS Est. Next Quarter
-0.76
Insider Transactions
-4.98
Institutional Transactions
-6.47
Beta
1.01
Average Sales Estimate Current Quarter
26
Average Sales Estimate Next Quarter
27
Fair Value
Quality Score
35
Growth Score
38
Sentiment Score
92
Actual DrawDown %
72.9
Max Drawdown 5-Year %
-84.3
Target Price
28.42
P/E
Forward P/E
PEG
P/S
7.19
P/B
1.39
P/Free Cash Flow
EPS
-1.24
Average EPS Est. Cur. Y
-3.08
EPS Next Y. (Est.)
-2.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-73.2
Relative Volume
0.62
Return on Equity vs Sector %
-41.9
Return on Equity vs Industry %
-25.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.46
EBIT Estimation
◆
XNCR
Healthcare
$12.31
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
51.9
Range 1M
58.4%
Sup Dist
1.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-134.2%
EPS NY
11.1%
52W%
44.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+130.9% upside
Upside
+130.9%
Quality
35
Xencor, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 260
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
XNCR
Latest News
—
Caricamento notizie per XNCR…
stock quote shares XNCR – Xencor Inc Stock Price stock today
news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch XNCR – Xencor Inc yahoo finance google finance
stock history XNCR – Xencor Inc invest stock market
stock prices XNCR premarket after hours
ticker XNCR fair value insiders trading